EUVIMEDEUVIMED entdecken
Crossref

An Optimized Cancer Cachexia Research Model

Yushan Wan, Dongfang Li, Chen Chen, Yirong Xu, Bo Yuan, Fangyi Ding, Jian Peng, Zhehan Ma, Huike Zhang, Zhixiang Zhang

Current Protocols · 2026-11 · 6 (11)

DOI: 10.1002/cpz1.70506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Protocols, online erschienen am 30.10.2026. Verfasst von Yushan Wan und 9 weiteren Autor:innen. Beteiligte Einrichtung: In vivo Pharmacology Unit, WuXi Biology, WuXi AppTec Co., Ltd, Shanghai, China. Hauptthemen laut MEDLINE: Cachexia, Disease Models, Animal, Neoplasms. Die Arbeit nennt 24 Literaturangaben. Gefördert von: WuXi AppTec.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cachexia (CC) is a severe and frequently irreversible systemic syndrome marked by significant weight loss, primarily affecting skeletal muscle and adipose tissue. Cachexia occurs in 50% to 80% of patients with cancer and accounts for up to 20% of cancer‐related deaths. While various factors interact to induce cachexia, the precise mechanisms underlying this clinical condition are not fully understood. Currently, there are no approved pharmacological treatments for CC, highlighting the urgent need for developing novel experimental models. Here, we developed an optimized protocol for CC research by injecting HT1080 cells into BALB/c nude female mice and observed a body weight loss, fat and muscle decrease, worsened physical performance, and a trend of increased proinflammatory cytokines. © 2026 Wiley Periodicals LLC. Basic Protocol 1 : Generation of a cancer cachexia model Basic Protocol 2 : Cancer cachexia mice monitoring, behavior test, and sample processing

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaDisease Models, AnimalNeoplasmsAnimalsFemaleMiceHumansMice, Inbred BALB CMice, NudeCell Line, TumorMuscle, Skeletal

Stichwörter der Autor:innen

HT1080 tumor modelcachexiacancercell‐line derived xenograft modelstumortumor complications

Autor:innen und Institutionen

  • In vivo Pharmacology Unit, WuXi Biology, WuXi AppTec Co., Ltd, Shanghai, China.
  • These authors contributed equally to this work.
  • In vivo pharmacology Unit, WuXi Biology, WuXi AppTec Co., Ltd, Nantong, China.

Förderung

  • WuXi AppTec

Zitieren

APA

Wan, Y., Li, D., Chen, C., Xu, Y., Yuan, B., Ding, F., Peng, J., Ma, Z., Zhang, H., & Zhang, Z. (2026). An Optimized Cancer Cachexia Research Model. Current Protocols, 6(11). https://doi.org/10.1002/cpz1.70506

Vancouver

Wan Y, Li D, Chen C, Xu Y, Yuan B, Ding F, et al. An Optimized Cancer Cachexia Research Model. Current Protocols. 2026;6(11). doi:10.1002/cpz1.70506

BibTeX
@article{Wan2026,
  author = {Wan, Yushan and Li, Dongfang and Chen, Chen and Xu, Yirong and Yuan, Bo and Ding, Fangyi and Peng, Jian and Ma, Zhehan and Zhang, Huike and Zhang, Zhixiang},
  title = {An Optimized Cancer Cachexia Research Model},
  journal = {Current Protocols},
  year = {2026},
  volume = {6},
  number = {11},
  doi = {10.1002/cpz1.70506}
}
Kostenlos starten →